194 related articles for article (PubMed ID: 34970530)
1. Design, Synthesis, Chemical and Biochemical Insights Into Novel Hybrid Spirooxindole-Based p53-MDM2 Inhibitors With Potential Bcl2 Signaling Attenuation.
Aziz YMA; Lotfy G; Said MM; El Ashry ESH; El Tamany ESH; Soliman SM; Abu-Serie MM; Teleb M; Yousuf S; Dömling A; Domingo LR; Barakat A
Front Chem; 2021; 9():735236. PubMed ID: 34970530
[TBL] [Abstract][Full Text] [Related]
2. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098
[TBL] [Abstract][Full Text] [Related]
3. Optimized spirooxindole-pyrazole hybrids targeting the p53-MDM2 interplay induce apoptosis and synergize with doxorubicin in A549 cells.
Islam MS; Al-Majid AM; Sholkamy EN; Barakat A; Viale M; Menichini P; Speciale A; Loiacono F; Azam M; Verma VP; Yousuf S; Teleb M
Sci Rep; 2023 May; 13(1):7441. PubMed ID: 37156796
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of new substituted spirooxindoles as potential inhibitors of the MDM2-p53 interaction.
Barakat A; Islam MS; Ghawas HM; Al-Majid AM; El-Senduny FF; Badria FA; Elshaier YAMM; Ghabbour HA
Bioorg Chem; 2019 May; 86():598-608. PubMed ID: 30802707
[TBL] [Abstract][Full Text] [Related]
5. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 Interaction.
Gollner A; Rudolph D; Arnhof H; Bauer M; Blake SM; Boehmelt G; Cockroft XL; Dahmann G; Ettmayer P; Gerstberger T; Karolyi-Oezguer J; Kessler D; Kofink C; Ramharter J; Rinnenthal J; Savchenko A; Schnitzer R; Weinstabl H; Weyer-Czernilofsky U; Wunberg T; McConnell DB
J Med Chem; 2016 Nov; 59(22):10147-10162. PubMed ID: 27775892
[TBL] [Abstract][Full Text] [Related]
7. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
[TBL] [Abstract][Full Text] [Related]
8. Corrigendum to "Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators" [Bioorg. Chem. 117 (2021) 105427].
Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
Bioorg Chem; 2024 Feb; 143():107013. PubMed ID: 38087753
[No Abstract] [Full Text] [Related]
9. Exploring pyrrolidinyl-spirooxindole natural products as promising platforms for the synthesis of novel spirooxindoles as EGFR/CDK2 inhibitors for halting breast cancer cells.
Nafie MS; Al-Majid AM; Ali M; Alayyaf AA; Haukka M; Ashraf S; Ul-Haq Z; El-Faham A; Barakat A
Front Chem; 2024; 12():1364378. PubMed ID: 38487783
[TBL] [Abstract][Full Text] [Related]
10. Targeted Synthesis of Complex Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2-p53 Inhibitors.
Gollner A; Weinstabl H; Fuchs JE; Rudolph D; Garavel G; Hofbauer KS; Karolyi-Oezguer J; Gmaschitz G; Hela W; Kerres N; Grondal E; Werni P; Ramharter J; Broeker J; McConnell DB
ChemMedChem; 2019 Jan; 14(1):88-93. PubMed ID: 30458062
[TBL] [Abstract][Full Text] [Related]
11. Regio- and stereoselective synthesis of new spirooxindoles via 1,3-dipolar cycloaddition reaction: Anticancer and molecular docking studies.
Lotfy G; El Ashry ESH; Said MM; El Tamany ES; Abdel Aziz YM; Al-Dhfyan A; Al-Majid AM; Barakat A
J Photochem Photobiol B; 2018 Mar; 180():98-108. PubMed ID: 29413708
[TBL] [Abstract][Full Text] [Related]
12. Halting Tumor Progression via Novel Non-Hydroxamate Triazole-Based Mannich Bases MMP-2/9 Inhibitors; Design, Microwave-Assisted Synthesis, and Biological Evaluation.
Albelwi FF; Teleb M; Abu-Serie MM; Moaty MNAA; Alsubaie MS; Zakaria MA; El Kilany Y; Aouad MR; Hagar M; Rezki N
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638665
[TBL] [Abstract][Full Text] [Related]
13. An oral 2-hydroxypropyl-β-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1/2 in hepatocellular carcinoma.
Gao X; Wei M; Shan W; Liu Q; Gao J; Liu Y; Zhu S; Yao H
Pharmacol Res; 2019 Oct; 148():104400. PubMed ID: 31425749
[TBL] [Abstract][Full Text] [Related]
14. One-pot synthesis of spiro(indoline-3,4'-pyrazolo[3,4-b]pyridine)-5'-carbonitriles as p53-MDM2 interaction inhibitors.
Ibrahim HS; Eldehna WM; Fallacara AL; Ahmed ER; Ghabbour HA; Elaasser MM; Botta M; Abou-Seri SM; Abdel-Aziz HA
Future Med Chem; 2018 Dec; 10(24):2771-2789. PubMed ID: 30526032
[TBL] [Abstract][Full Text] [Related]
15. Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.
Patil SP; Pacitti MF; Gilroy KS; Ruggiero JC; Griffin JD; Butera JJ; Notarfrancesco JM; Tran S; Stoddart JW
J Comput Aided Mol Des; 2015 Feb; 29(2):155-63. PubMed ID: 25377899
[TBL] [Abstract][Full Text] [Related]
16. Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma.
Wang B; Peng F; Huang W; Zhou J; Zhang N; Sheng J; Haruehanroengra P; He G; Han B
Acta Pharm Sin B; 2020 Aug; 10(8):1492-1510. PubMed ID: 32963945
[TBL] [Abstract][Full Text] [Related]
17. Reinvestigation of Passerini and Ugi scaffolds as multistep apoptotic inducers
Ayoup MS; Wahby Y; Abdel-Hamid H; Abu-Serie MM; Ramadan S; Barakat A; Teleb M; Ismail MMF
RSC Adv; 2023 Sep; 13(40):27722-27737. PubMed ID: 37736568
[TBL] [Abstract][Full Text] [Related]
18. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
Reuther C; Heinzle V; Nölting S; Herterich S; Hahner S; Halilovic E; Jeay S; Wuerthner JU; Aristizabal Prada ET; Spöttl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):1-19. PubMed ID: 27871087
[TBL] [Abstract][Full Text] [Related]
19. Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity.
Zhao Q; Xiong SS; Chen C; Zhu HP; Xie X; Peng C; He G; Han B
Front Oncol; 2022; 12():972372. PubMed ID: 35992773
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas.
Valassiadou KE; Stefanaki K; Tzardi M; Datseris G; Georgoulias V; Melissas J; Tsiftsis DD; Delides G; Kanavaros P
Anticancer Res; 1997; 17(4A):2571-6. PubMed ID: 9252682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]